Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.
作者信息
Krowka Michael J
机构信息
Department of Medicine, Division of Pulmonary and Critical Care, Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN.
出版信息
Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S13-S24. doi: 10.1002/cld.846. eCollection 2020 Feb.
Abstract
摘要
相似文献
1
Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.
Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S13-S24. doi: 10.1002/cld.846. eCollection 2020 Feb.
2
Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome.
J Hepatol. 1999 Dec;31(6):1075-9. doi: 10.1016/s0168-8278(99)80321-3.
3
Pulmonary vascular disorders in portal hypertension.
Eur Respir J. 1998 May;11(5):1153-66. doi: 10.1183/09031936.98.11051153.
4
Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment.
Liver Int. 2015 Jun;35(6):1646-60. doi: 10.1111/liv.12791. Epub 2015 Feb 16.
5
Response to Sildenafil in a Patient With Coexisting Post-Liver Transplant Portopulmonary Hypertension and Hepatopulmonary Syndrome.
Exp Clin Transplant. 2017 Dec;15(6):693-695. doi: 10.6002/ect.2015.0210. Epub 2016 Mar 21.
6
Hepatopulmonary syndrome and portopulmonary hypertension.
Hepatol Res. 2009 Oct;39(10):1020-2. doi: 10.1111/j.1872-034X.2009.00552.x.
7
Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation.
J Clin Gastroenterol. 2010 Aug;44(7):e136-40. doi: 10.1097/MCG.0b013e3181da76fc.
8
Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era.
Liver Transpl. 2004 Oct;10(10 Suppl 2):S54-8. doi: 10.1002/lt.20260.
9
Hepatopulmonary syndrome and portopulmonary hypertension.
Hosp Pract (1995). 2013 Apr;41(2):62-71. doi: 10.3810/hp.2013.04.1049.
10
Pulmonary Complications of Portal Hypertension.
Clin Liver Dis. 2019 Nov;23(4):683-711. doi: 10.1016/j.cld.2019.06.003. Epub 2019 Aug 9.
引用本文的文献
1
Rare but serious: pulmonary vascular disease around the world.
JHLT Open. 2025 Jul 18;9:100327. doi: 10.1016/j.jhlto.2025.100327. eCollection 2025 Aug.
2
Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography.
Sci Rep. 2025 Jul 1;15(1):21075. doi: 10.1038/s41598-025-08376-6.
3
Cardiac Evaluation in Liver Transplant Candidates.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102554. doi: 10.1016/j.jceh.2025.102554. Epub 2025 Mar 27.
4
History of the liver-heart relationship.
Clin Liver Dis (Hoboken). 2024 Apr 26;23(1):e0151. doi: 10.1097/CLD.0000000000000151. eCollection 2024 Jan-Jun.
5
Utility of transesophageal echocardiography during orthotopic liver transplantation: A narrative review.
Ann Card Anaesth. 2023 Oct-Dec;26(4):367-379. doi: 10.4103/aca.aca_186_22.
6
Human liver single nuclear RNA sequencing implicates BMPR2, GDF15, arginine, and estrogen in portopulmonary hypertension.
Commun Biol. 2023 Aug 9;6(1):826. doi: 10.1038/s42003-023-05193-3.
7
Hepatopulmonary Syndrome in a Patient With Autoimmune Hepatitis and Chronic Hepatitis C: A Case Report Highlighting Typical Echo Findings.
Cureus. 2023 Jul 7;15(7):e41491. doi: 10.7759/cureus.41491. eCollection 2023 Jul.
8
Cardiac risk stratification of the liver transplant candidate: A comprehensive review.
World J Transplant. 2022 Jul 18;12(7):142-156. doi: 10.5500/wjt.v12.i7.142.
9
Pulmonary complications of portal hypertension: The overlooked decompensation.
World J Clin Cases. 2022 Jun 16;10(17):5531-5540. doi: 10.12998/wjcc.v10.i17.5531.
10
Pulmonary Hypertension as a Rare Complication After Orthotopic Liver Transplant in a Patient With Non-alcoholic Steatohepatitis (NASH) Cirrhosis Complicated by Hepatopulmonary Syndrome.
Cureus. 2022 May 4;14(5):e24740. doi: 10.7759/cureus.24740. eCollection 2022 May.
本文引用的文献
1
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Lancet Respir Med. 2019 Jul;7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8. Epub 2019 Jun 6.
2
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Liver Transpl. 2019 Aug;25(8):1155-1164. doi: 10.1002/lt.25438. Epub 2019 May 30.
3
Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.
Eur Respir J. 2019 Jan 31;53(2). doi: 10.1183/13993003.01096-2018. Print 2019 Feb.
4
Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.
Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.
5
Does Portopulmonary Hypertension Impede Liver Transplantation in Cirrhotic Patients? A French Multicentric Retrospective Study.
Transplantation. 2018 Apr;102(4):616-622. doi: 10.1097/TP.0000000000001981.
6
Predictors of Waitlist Mortality in Portopulmonary Hypertension.
Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.
7
Frequency and Outcomes of Patients With Increased Mean Pulmonary Artery Pressure at the Time of Liver Transplantation.
Transplantation. 2017 Jan;101(1):101-106. doi: 10.1097/TP.0000000000001517.
8
Portopulmonary hypertension: Still an appropriate consideration for liver transplantation?
Liver Transpl. 2016 Dec;22(12):1637-1642. doi: 10.1002/lt.24625. Epub 2016 Nov 5.
9
International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.
Transplantation. 2016 Jul;100(7):1440-52. doi: 10.1097/TP.0000000000001229.
10
What's new in the treatment of portopulmonary hypertension?
Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):983-92. doi: 10.1586/17474124.2015.1035647. Epub 2015 Apr 16.
Zotero 插件